BioCentury
ARTICLE | Clinical News

GI-5005: Additional Phase IIb data

April 26, 2010 7:00 AM UTC

A retrospective analysis of 96 treatment-naïve patients from an open-label Phase IIb trial showed that GI-5005 plus SOC ( Copegus ribavirin and Pegasys peginterferon alfa-2a) led to improved ETR resp...